The BET inhibitors induce apoptosis of primary MCL cells that are either sensitive or resistant to ibrutinib, coupled with a reduced expression of MYC, BCL2, CDK4/6, and NFκB targeted genes [99]. The gene discussed is NFKB1; the disease is mantle cell lymphoma.